Monday, January 09, 2017 11:39:05 AM
In health care stocks news, Exact Sciences(EXAS) was up 16.6% after the company said Sunday it expects to report revenues between $34.9 million and $35.4 million in Q4, up 142% year-over-year and above the $30.1 million consensus estimate from analysts polled by Capital IQ. For the year the company expects to report revenues between $99.0 million and $99.5 million, up 150% from a year ago and higher than the $94.2 million consensus. The maker of a colon-cancer screening test said 244,000 Cologuard tests were completed in 2016, a 134% increase. Exact said insurance coverage expanded by 67% during 2016.
"My goal in life is to be as good of a person as my dog already thinks I am."
—Author Unknown
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
